Mesa Laboratories, Inc. acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for ?80 million.
October 15, 2023
Share
Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for ?80 million on October 14, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for ?5 million.
Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 14, 2023. Of the total acquisition price of ?80 million, net of cash and debt, ?8.5 million will be held back for a period of 18 months from the acquisition closing date as security against potential indemnification losses. The acquisition was funded through a combination of cash on-hand and ?61.3809 million borrowed under our line of credit.
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.